Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

Puma Biotechnology and Pierre Fabre enter into an exclusive license agreement for the development and marketing of NERLYNX® (neratinib)

pharmafocusasiaApril 03, 2019

Tag: Puma Biotechnology , Pierre Fabre , Development

PharmaSources Customer Service